BioSpace News Archive

Inivata, a leader in liquid biopsy, announced the publication of new data in support of its RaDaR™ liquid biopsy test in patients with early-stage non-small cell lung cancer.

International medical imaging IT and cybersecurity company Sectra has signed a digital pathology contract with Erasmus University Medical Center in the Netherlands.

111, Inc. today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021.

The diagnostic company SphingoTec GmbH and Rivaara Labs Pvt Ltd. announced that they have entered into a multi-year distribution agreement for the commercialization of SphingoTec’s point of care diagnostic solutions in the Indian subcontinent.

X4 Pharmaceuticals, Inc. reported financial results for the fourth quarter and twelve months ended December 31, 2021, and provided a corporate update.

Invitae, a leading medical genetics company, announced full access to its Personalized Cancer Monitoring platform to help detect minimal or molecular residual disease in patients with solid tumors.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present and participate in a panel discussion at the 3rd Annual STING & TLR-Targeting Therapies Summit taking place virtually from March 22-24, 2022.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its fourth quarter and full year 2021 financial results after market close on Thursday, March 24, 2022.

Aadi Bioscience, Inc., a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.